Persistent Asset Partners’s Outlook Therapeutics OTLK Stock Holding History

Persistent Asset Partners’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$114K	Buy	+198,655	New	+$189K	0.03%	267

Other funds holding OTLK

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $375B AUM 21.05% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Winton Group London, United Kingdom $2.58B AUM 26.15% 1-Year Est. Return

Persistent Asset Partners's OTLK Position: Q3 2026 in Review

Persistent Asset Partners opened a new position in Outlook Therapeutics (OTLK) in Q3 2026: 198,655 shares worth $114K. The stake represents 0.03% of the portfolio and ranks #267 among its holdings.

54 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.

Persistent Asset Partners held 198,655 shares of Outlook Therapeutics worth $114K as of Q3 2026.
Outlook Therapeutics was a new Persistent Asset Partners position in Q3 2026.
Outlook Therapeutics made up 0.03% of Persistent Asset Partners's portfolio in Q3 2026, its #267 holding.
54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.

Based on Persistent Asset Partners's 13F filing for Q3 2026, filed 13 Nov 2026.